HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.

Abstract
Although HIV-associated multicentric Castleman disease (HIV-MCD) is not classified as an AIDS-defining illness, mortality is high and progression to lymphoma occurs frequently. At present, there is no widely accepted recommendation for the treatment of HIV-MCD. In this retrospective (1998-2010), multicentric analysis of 52 histologically proven cases, outcome was analyzed with respect to the use of different MCD therapies and potential prognostic factors. After a mean follow-up of 2.26 years, 19 of 52 patients died. Median estimated overall survival (OS) was 6.2 years. Potential risk factors, such as older age, previous AIDS, or lower CD4 T cells had no impact on OS. Treatment was heterogeneous, consisting of cytostatic and/or antiviral agents, rituximab, or combinations of these modalities. There were marked differences in the outcome when patients were grouped according to MCD treatment. Patients receiving rituximab-based regimens had higher complete remission rates than patients receiving chemotherapy only. The mean estimated OS in patients receiving rituximab alone or in combination with cytostatic agents was not reached, compared with 5.1 years (P = .03). Clinical outcome and overall survival of HIV-MCD have markedly improved with rituximab-based therapies, considering rituximab-based therapies (with or without cytostatic agents) to be among the preferred first-line options in patients with HIV-MCD.
AuthorsChristian Hoffmann, Holger Schmid, Markus Müller, Christian Teutsch, Jan van Lunzen, Stefan Esser, Timo Wolf, Christoph Wyen, Michael Sabranski, Heinz-August Horst, Stefan Reuter, Martin Vogel, Hans Jäger, Johannes Bogner, Keikawus Arasteh
JournalBlood (Blood) Vol. 118 Issue 13 Pg. 3499-503 (Sep 29 2011) ISSN: 1528-0020 [Electronic] United States
PMID21778341 (Publication Type: Evaluation Study, Journal Article, Multicenter Study)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (adverse effects, therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Castleman Disease (diagnosis, drug therapy, etiology, mortality)
  • Cohort Studies
  • Female
  • HIV Infections (complications, diagnosis, drug therapy, mortality)
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Rituximab
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: